Abiopharma

🔍 Rodman David Malcom (Executive)

Company: Mineralys Therapeutics, Inc. (MLYS)

Report Date: 2026-08-10

Detailed Transactions and Holdings:

• Acquired 2,170 shares of Common Stock at $16.0 per share (Direct)
  Date: 2026-08-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 53,554.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,170 shares of Common Stock at $27.09 per share (Direct)
  Date: 2026-08-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 51,384.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,170 shares of Stock Option at $16.0 per share (Derivative)
  Date: 2026-08-10 | Code: M | Expires: 2033-02-09 | equity_swap_involved: 0 | shares_owned_after: 13,024.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
• F2: The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter.